Thryv Earns Top 50 Spot on G2's 2025 Best Software Awards for Best Marketing and Digital Advertising Products
DALLAS, February 25, 2025--(BUSINESS WIRE)--Thryv® (NASDAQ: THRY), provider of the leading small business marketing and sales software platform, today announced a Top 50 placement in G2's 2025 Best Software Awards in the category of Best Marketing and Digital Advertising products. The annual Best Software Awards rank the world's best software companies and products based on authentic, timely reviews from real users.
Receiving this Best Software Award underscores Thryv's commitment to small business marketing innovations that automate and streamline the process of attracting and converting prospects into loyal customers.
"We design our products expressly to meet the needs of small businesses because most don't have the resources to build a marketing engine while also running their day-to-day," said Rees Johnson, Thryv's Chief Product Officer. "We leverage the best in AI and marketing automations so our small business clients can grow efficiently. This award is special because it validates the strength of our client relationships and the value they are realizing from our marketing platform."
Thryv Marketing Center™ offers small businesses: a professionally designed website, social media management with CaptionAI, AI review response, online listings and reviews, and real time analytics, all designed to flex and scale as a small business grows. Thryv clients also receive unlimited training and 24/7 support through email, online chat or by phone.
"The stakes for choosing the right business software are higher than ever," said Godard Abel, co-founder & CEO at G2. "With over 180,000 software products and services listings and 2.8 million verified user reviews in the G2 marketplace, we're proud to help companies navigate these critical choices with insights rooted in authentic customer feedback. The 2025 Best Software Award winners represent the very best in the industry, standing out for their exceptional performance and customer satisfaction. Congratulations to this year's honorees!"
As the world's largest and most trusted software marketplace, G2 reaches 100 million buyers annually. To learn more, view G2's 2025 Best Software Awards and read more about G2's methodology.
ABOUT THRYV
Thryv Holdings, Inc. (NASDAQ:THRY) is the provider of the leading sales and marketing platform designed to help small businesses attract new and repeat customers. Thryv software offers SMBs everything they need to manage day-to-day operations and grow efficiently. The platform's AI-supported marketing and business automations help business owners save time, compete, and win. More than 100K businesses globally use Thryv software to connect with customers and run and grow their business. For more information, visit www.thryv.com.
About G2
G2 is the world's largest and most trusted software marketplace. More than 100 million people annually — including employees at all Fortune 500 companies — use G2 to make smarter software decisions based on authentic peer reviews. Thousands of software and services companies of all sizes partner with G2 to build their reputation and grow their business — including Salesforce, HubSpot, Zoom, and Adobe. To learn more about where you go for software, visit www.g2.com and follow us on X and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225971921/en/
Contacts
Media Contacts: Julie MurphyThryv, Inc.617.967.5426julie.murphy@thryv.com
Investor Contact: Cameron LessardThryv, Inc.cameron.lessard@thryv.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA) today announced partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLE) from both PADOVA and the Phase II PASADENA study. 'As pioneers in developing the first anti-alpha-synuclein targeting antibody, we are excited to see Roche advancing prasinezumab into Phase III development, with the potential to deliver the first disease-modifying treatment option to the millions of individuals living with Parkinson's disease and their families,' stated Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks (two years) were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology. The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease, are ongoing. About Prasinezumab Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. Data from the Phase IIb PADOVA study suggest the possible clinical benefit of prasinezumab on top of effective symptomatic treatment in early-stage Parkinson's disease. PADOVA investigated prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01], although the study missed statistical significance (p=0.0657). In a pre-specified analysis, the effect of prasinezumab was more pronounced in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99], p=0.0431 (nominal). Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Trends towards reduced motor progression at 104 weeks (two years) were observed, showing 30-40% relative reduction versus placebo across the overall and levodopa-treated populations. Prasinezumab continues to be well tolerated and no new safety signals were observed in the study. The safety database for prasinezumab consists of data from more than 900 Parkinson's disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. In December 2013, Prothena and Roche entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab. Roche has sole responsibility for developing and commercializing prasinezumab and has agreed to pay Prothena up to double-digit teen royalties on net sales. To date, Prothena has earned $135 million with up to $620 million in additional milestone payments that include regulatory and sales milestones. In addition, Prothena has an option to co-promote prasinezumab in the U.S. About Parkinson's disease Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells. Today, Parkinson's disease affects over 10 million people worldwide. The prevalence of Parkinson's disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available. However, no therapies slow down or stop the clinical progression of Parkinson's disease. About Prothena Prothena Corporation plc is a clinical-stage biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Parkinson's disease and a number of other neurodegenerative diseases. For more information, please visit the Company's website at and follow the Company on X (formerly Twitter) @ProthenaCorp. Forward-Looking Statements This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design, and proposed mechanism of action prasinezumab; plans for ongoing and future clinical trials of prasinezumab; and amounts we might receive under our collaboration with Roche. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the 'Risk Factors' sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
Business Wire
42 minutes ago
- Business Wire
Université de Moncton and Dassault Systèmes Partner to Solve Urban Development Challenges in Canada with Virtual Twins
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- Dassault Systèmes (Euronext Paris: FR0014003TT8, and the Université de Moncton, Canada's largest French-language university outside Québec, today announced the launch of a new project aimed to solve housing, urban densification and ecological conservation challenges in the southeastern region of New Brunswick, Canada. The partnership was signed at VivaTech 2025 in Paris. The six-month project will develop collaborative virtual environments to model, analyze and plan sustainable urban development in the cities of Dieppe and Moncton - two of Canada's fastest growing metropolitan areas in the last 20 years - all while establishing a protected wildlife corridor in the southeastern part of New Brunswick. In addition to the Université de Moncton and Dassault Systèmes, the project brings together several Canadian partners: the cities of Dieppe and Moncton, the Southeast Regional Service Commission, Collège Communautaire du Nouveau-Brunswick, and the New Brunswick-based businesses Black Arcs and Remsoft. Dassault Systèmes will use its 3DEXPERIENCE platform to create, maintain and analyze a virtual twin of a zone in New Brunswick measuring approximately 386 miles² (1,000 km²). This virtual twin is enriched with territorial data on buildings, zoning, mobility, biodiversity and more, provided by the partners. Stakeholders will use this virtual twin to share information, test and evaluate different planning scenarios, evaluate the impacts of urban densification, and make informed decisions to optimize housing planning and preserve ecological corridors that are essential to the region's environmental wellbeing. 'Our partnership will enable the Université de Moncton to benefit from a large-scale territory virtual twin that is delivered quickly through a managed solution that reduces costs and risks. Local stakeholders will be able to simulate what-if scenarios, evaluate options and take informed decisions – all on the 3DEXPERIENCE platform – to solve complex real-life challenges and optimize quality of life in the region of New Brunswick,' said Josephine Ong, Vice President, Cities and Public Services Industry, Dassault Systèmes. 'This partnership with Dassault Systèmes positions the Université de Moncton at the forefront of digital innovation applied to urban and environmental issues. We are proud to put our expertise at the service of a project with strong regional and international impact,' said Francis LeBlanc, associate vice-rector for research and dean of the Faculty of Graduate Studies and Research, Université de Moncton. This collaboration was made possible thanks to the support of Opportunities New Brunswick (ONB), which played a key role in fostering the connection between Dassault Systèmes and the Université de Moncton. 'New Brunswick is truly a hub of innovation and collaboration. This partnership demonstrates the strength of the connections between research, industry, and regional development. Together, we are creating solutions that have a real local impact and significant global potential,' said Luke Randall, minister responsible for Opportunities New Brunswick. This project represents an important step forward for urban development in New Brunswick. By combining Dassault Systèmes' technology with local expertise, it will help plan city growth more effectively while protecting the environment. The approach could also serve as a model for other regions in Canada and beyond. ### About Dassault Systèmes Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes' 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: About the Université de Moncton Founded in 1963 in New Brunswick, the Université de Moncton is the largest French-language university in Canada outside Quebec, with three campuses in Edmundston, Moncton and Shippagan. Its mission is to transmit knowledge, advance research and contribute to the development of its community, by training committed, creative people who are open to the world. The Université de Moncton also plays an important role in the development of the Acadian and francophone community, regionally, nationally and internationally. For more information, visit: About Opportunities New Brunswick Opportunities New Brunswick is a Crown corporation and the lead economic development agency for the Government of New Brunswick, Canada. It seeks to attract and support opportunities to stimulate the economy and create jobs by providing support services for businesses. For more information, visit:
Business Wire
an hour ago
- Business Wire
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust Company, and Equiniti (the dividend paying agent retained by the SINOVAC Board), which may prevent the SINOVAC Board from paying the US$55.00 special dividend as scheduled on or about July 9, 2025. We learned that Vivo Capital's counsel informed the paying agent that Vivo would challenge the dividend and asked the paying agent to withdraw from facilitating the distribution of the US$55.00 dividend declared by the SINOVAC Board to all valid shareholders. The SINOVAC Board has an obligation to answer this Petition on behalf of all SINOVAC common shareholders to stand up to the egregious actions of Prime Success. We expect to file our Opposition Brief today at 5:00 p.m. Atlantic Standard Time, followed by a hearing on Wednesday, June 18. We continue to be shocked by the self-serving, unnecessary actions by Advantech and Vivo Capital (together known as the 'Dissenting Investor Group') against SINOVAC, threatening the rightful dividend payment to all valid SINOVAC common shareholders. These incomprehensible actions are unacceptable to the SINOVAC Board because: The Dissenting Investor Group has already pocketed more than US$1.1 billion in dividends from SINOVAC's operating subsidiary, while all SINOVAC's valid shareholders received nothing. An amount equal to the aggregate amount of cash that would be payable under the US$55.00 per common share special dividend in respect of the 2018 PIPE shares has been set aside by the SINOVAC Board in an escrow account managed by an independent third party pending final resolution of the legal proceedings, which the Dissenting Investor Group initiated. Thus, there is no risk whatsoever that the Dissenting Investor Group's allocations of the dividend will not be paid if the courts ultimately decide in their favor regarding the PIPE shares. These new actions by the Dissenting Investor Group go against their assertions of their support of the US$55.00 dividend payment in their letters to shareholders and raises the question – how can you trust anything they say in their letters or press releases? The SINOVAC Board will continue to fight these frivolous lawsuits, all of which aim to accomplish one thing: to allow the Dissenting Investor group to double dip on dividends. We feel certain we will prevail quickly in this and other proceedings. The SINOVAC Board is on a mission to restore fairness and deliver value to ALL SINOVAC shareholders. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of filings, hearings and other litigation-related matters, all of which are difficult to predict and many of which are beyond the Company's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
